Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.56 |
| ▸ | CDK9 | P50750 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 9/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3690362 | 0.86 | HTR2C (0.61) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL2269949 | 0.86 | HTR2C (0.61) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL29882300 | 0.86 | HTR2C (0.61) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL17234795 | 0.83 | HTR2C (0.53) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL24727966 | 0.83 | HTR2C (0.50) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL4698458 | 0.82 | HTR2C (0.46) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL2783025 | 0.81 | HTR2C (0.54) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL24158033 | 0.81 | HTR2C (0.54) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL24196806 | 0.80 | SIGMAR1 (0.55) | CCNT1CDK9HTR2CSIGMAR1KDM4E | |
| SCHEMBL31348189 | 0.80 | CCNT1 (0.60) | CCNT1CDK9HTR2CSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1768958-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2005121088-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | CCNT1 1007/4885CDK9 313/4885HTR2C 1793/4885 |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | DRD2, DRD4, HTR4 | CCNT1 2279/4885CDK9 1996/4885HTR2C 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.